復星醫藥(02196.HK)夥BioNTech向中國售1億劑新型肺炎疫苗 提成65%
復星醫藥(02196.HK)公布,與BioNTech訂立有關許可協議的第一號修訂協議,修訂許可協議項下有關新型肺炎疫苗產品於中國大陸、香港及澳門的銷售提成條款,就由BioNTech供應的成品,復星醫藥產業與BioNTech分別按年度銷售毛利的65%及35%的比率享有銷售提成,另外就由BioNTech供應的大包裝製劑,復星醫藥產業與BioNTech分別按年度銷售毛利的60%及40%的比率享有銷售提成。
另外BioNTech附屬BioNTech Manufacturing GmbH、復星醫藥產業及BioNTech,就有關BioNTech Manufacturing向其於中國大陸供應新型肺炎疫苗產品訂立供貨協議,根據供貨協議,在新型肺炎疫苗產品獲得中國大陸上市批准,且復星醫藥產業根據供應協議下達相應訂單的情況下,BioNTech Manufacturing承諾於2021年向中國大陸供應不少於1億劑新型肺炎疫苗產品。
就首批5,000萬劑新型肺炎疫苗產品的預付款,復星醫藥產業應在今年12月30日前支付金額為1.25億歐元的部分首付款,其餘1.25億歐元之首付款應於新型肺炎疫苗產品在中國大陸獲批上市後支付。復星醫藥產業應在新型肺炎疫苗產品交付後按照BioNTech Manufacturing發出的賬單支付首批新型肺炎疫苗產品供應的餘款,受限於根據供貨協議條款按年進行最終結算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.